Predictive factors and long-term visual outcomes after anti-vascular endothelial growth factor treatment of retinal angiomatous proliferation
Clinical Ophthalmology Oct 11, 2019
Maruyama-Inoue M, et al. - In this retrospective observational study, researchers reported findings of 9-year follow-up examinations and predictive factors for visual acuity outcome following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents to treat retinal angiomatous proliferation (RAP). The study sample consisted of 85 treatment-naïve eyes in 61 patients (mean age was 84.0 years) treated with intravitreal injections of anti-VEGF agents. As an induction treatment, all patients are given three consecutive monthly injections. Data reported that the mean BCVA gradually reduced from 0.58 at baseline to 0.70 at 36 months, 0.82 at 48 months, and 0.92 at 108 months. Baseline visual acuity and central foveal thickness were associated with visual acuity improvement at the final visits. With the use of intravitreal injections of anti-VEGF agents, it was difficult to achieve long-term stabilization of vision in RAP patients, regardless of treatment modality. In order to maintain visual acuity in patients with RAP, earlier diagnosis and treatment are necessary.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries